Precision Neuroscience
- Company typePrivate
- Founded2021
- HeadquartersManhattan, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Precision Neuroscience firmographics
Firmographics- Name
- Precision Neuroscience
- Legal name
- Precision Neuroscience Corporation
- Website
- https://precisionneuro.io
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Precision Neuroscience industry classification
Industry- Product category
- Brain-Computer Interface Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
- akta.pro secondary industry
- Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)
Keywords
Where Precision Neuroscience is headquartered
LocationHeadquarters
- HQ city
- Manhattan
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Precision Neuroscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Brain-Computer Interface Medical Devices: Precision Neuroscience is pre-revenue, having received FDA 510(k) clearance in April 2025 for its Layer 7 Cortical Interface. The company is transitioning from clinical development toward commercialization. Future revenue is expected from sale of implantable BCI devices and related surgical/clinical services to healthcare providers and patients with paralysis.
- Neural Data Services: The company is building and leveraging a neural dataset spanning over 75 patients across multiple brain regions. This neural data has potential applications in drug discovery, AI training, and neurological disease treatment research.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels8 records
Precision Neuroscience product offering
Product offeringCore offering
Precision Neuroscience develops and manufactures the Layer 7 Cortical Interface, a non-penetrating brain-computer interface system featuring a 1,024-electrode thin-film microelectrode array designed to be implanted on the brain surface via a minimally invasive micro-slit incision. The system uses AI software to translate neural signals into digital commands, enabling individuals with paralysis to operate computers, speech synthesizers, robotic limbs, and other digital devices using only their thoughts. The company received FDA 510(k) clearance in April 2025 for implantations up to 30 days and sells directly to hospital systems and clinical research institutions.
Product overview
Precision Neuroscience offers a single unified product, the Layer 7 Cortical Interface, a high-resolution brain-computer interface designed to help people with paralysis operate digital devices using only their thoughts. The system uses a non-penetrating surface electrode array with 1,024 electrodes that captures neural signals and translates them into digital commands via AI, enabling thought-based control of computers, speech synthesis, and external devices. The company operates its own 22,000 square foot MEMS fabrication facility in Addison, Texas for manufacturing the microelectrode arrays.
Differentiator
Problem solved
Functional benefit
Products and services
- Layer 7 Cortical Interface A non-penetrating brain-computer interface featuring a 1,024-electrode thin-film microelectrode array on an ultra-thin flexible film thinner than a human hair. The device gently conforms to the brain's surface, is implanted via a minimally invasive micro-slit incision in under 20 minutes, and uses AI software to translate brain signals into digital device commands. Designed for people with paralysis to operate computers, speech synthesizers, robotic limbs, and other digital devices through thought. Wireless, cosmetically discreet, and designed to be safely removable and upgradable without damaging brain tissue.
Quantifiable outcome
- 85+ patients successfully implanted with Layer 7 Cortical Interface across clinical studies
- +4 more outcomes
Companies that use Precision Neuroscience
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
Precision Neuroscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability4 records
Feature6 records
Precision Neuroscience partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core.
- UChicago MedicinecoreClinical partnership with UChicago Medicine's Sensorimotor Bionics Group to advance AI-driven sensorimotor function and neuroprosthetics research using Precision's Layer 7 cortical interface system. The collaboration builds on UChicago Medicine's decade-long involvement in landmark human BCI trials. Research aims to help patients with conditions like ALS or brainstem stroke better understand movement planning and execution, with potential applications in assistive technology and neurorehabilitation.
- MedtroniccoreStrategic partnership to integrate Precision's Layer 7 brain-computer interface with Medtronic's StealthStation surgical navigation system. The collaboration aims to provide neurosurgeons with real-time functional and structural brain information during operations by combining Precision's high-resolution electrode technology with Medtronic's 3D surgical navigation platform. The partnership is intended to accelerate clinical adoption of BCI technology and advance neurological care globally.
- WVU Rockefeller Neuroscience InstitutecoreExpanded partnership to complete first successful extended in-human clinical study using Layer 7 Cortical Interface, enabling monitoring of brain activity for up to 30 days in patients recovering from craniotomy procedures. The collaboration is supported by a National Science Foundation grant and builds on previous short-term procedures, laying groundwork for fully implantable brain-computer interface systems.
- Beth Israel Deaconess Medical CentercoreClinical research collaboration to expand BCI research using Precision's Layer 7 technology in various clinical settings.
- Mount SinaicoreClinical partner and co-founding institution. Dr. Benjamin Rapoport, co-founder and Chief Science Officer, is a neurosurgeon at Mount Sinai.
- Penn MedicinecoreClinical partner for BCI technology research and development.
- Johns Hopkins MedicinecoreClinical partner for BCI technology research and development.
- Mass General BrighamcoreClinical partner for BCI technology research and development.
- Northwestern MedicinecoreClinical partner for BCI technology research and development.
- Emory HealthcarecoreClinical partner for BCI technology research and development.
- Barrow Neurological InstitutecoreClinical partner for BCI technology research and development.
- NYU Langone HealthcoreClinical partner for BCI technology research and development.
- Michigan MedicinecoreClinical partner for BCI technology research and development.
- Thomas Jefferson UniversitycoreClinical partner for BCI technology research and development.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Precision Neuroscience competitors and assessment
Company assessmentDirect peers
- Neuralink: Neuralink is the most direct BCI competitor, developing high-bandwidth penetrating electrode implants (N1 chip) for paralysis and other indications. Multiple Precision executives are Neuralink co-founder alumni, and the two are routinely compared head-to-head in media coverage of the BCI category.
- Synchron: Synchron develops the Stentrode, a minimally invasive endovascular BCI that records neural signals via blood vessels, avoiding open brain surgery. Like Precision, it targets paralysis-driven digital device control and has received FDA breakthrough designation, positioning it as the closest clinical-stage alternative to Precision's Layer 7.
- Blackrock Neurotech: Blackrock Neurotech manufactures the Utah Array, a penetrating intracortical electrode used in academic BCI research and human clinical studies for paralysis and speech restoration. It is a direct competitor in the implantable BCI category serving similar patient populations and clinical research sites.
- Paradromics: Paradromics is developing the Connexus BCI, a high-data-rate intracortical implant for restoring speech and communication. It targets the same paralysis and speech-restoration use cases as Precision and is among the cohort of next-generation BCI companies pursuing FDA clinical studies.
Broad incumbents
- Medtronic: Medtronic is Precision's strategic integration partner (StealthStation surgical navigation) and a broad incumbent in neurosurgery and neuromodulation, including the Percept PC deep brain stimulator and Activa platform. Its installed base of neurosurgical navigation systems provides a distribution channel for Precision's Layer 7 and represents the dominant commercial channel in the space.
- Boston Scientific: Boston Scientific is a major neuromodulation incumbent with Vercise deep brain stimulation systems and a broad portfolio in functional neurosurgery. While not a BCI company, it competes in adjacent therapeutic stimulation indications Precision may eventually expand into (Parkinson's, epilepsy, depression).
- Abbott: Abbott operates the Infinity and Proclaim deep brain stimulation and spinal cord stimulation portfolios through its neuromodulation business. It is a broad incumbent in implantable neurostimulation that could compete with or partner alongside Precision in therapeutic indications beyond paralysis.
Emerging players
- InBrain Neuroelectronics: InBrain Neuroelectronics is developing graphene-based neural interfaces for both recording and therapeutic stimulation in CNS disorders. It overlaps with Precision on cortical surface electrode technology and shared indications (Parkinson's, epilepsy) but is at an earlier clinical stage.
- BrainGate: BrainGate is a long-running academic BCI consortium (Brown, MGH, Stanford, Emory, Providence VA) that has demonstrated intracortical control of cursors, robotic arms, and speech in patients with paralysis. It is an emerging competitor/potential partner on the research and clinical validation frontier where Precision also operates.
- Motif Neurotech: Motif Neurotech is developing minimally invasive cortical stimulators for mental health indications such as treatment-resistant depression. It shares Precision's minimally invasive, surface-electrode philosophy and represents an emerging adjacent platform targeting therapeutic neuromodulation via cortical access.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Precision Neuroscience social profiles
Digital presencePrecision Neuroscience compliance and trust
Trust signalCompliance1 record
Precision Neuroscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Precision Neuroscience leadership team
Management profileNumber of profiles
Profiles12 records
Precision Neuroscience funding detail
Funding detailFunding overview
Funding rounds5 records
Investors23 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Precision Neuroscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Precision Neuroscience
What does Precision Neuroscience do?
Precision Neuroscience develops and manufactures the Layer 7 Cortical Interface, a non-penetrating brain-computer interface system featuring a 1,024-electrode thin-film microelectrode array designed to be implanted on the brain surface via a minimally invasive micro-slit incision. The system uses AI software to translate neural signals into digital commands, enabling individuals with paralysis to operate computers, speech synthesizers, robotic limbs, and other digital devices using only their thoughts. The company received FDA 510(k) clearance in April 2025 for implantations up to 30 days and sells directly to hospital systems and clinical research institutions.
Is Precision Neuroscience a public or private company?
Precision Neuroscience is a private company. It is classified as venture growth investor backed and is currently operating.
When was Precision Neuroscience founded?
Precision Neuroscience was founded in 2021. It employs 101 to 250 people.
Where is Precision Neuroscience based?
Precision Neuroscience is headquartered in Manhattan, United States, in the North America region.
How does Precision Neuroscience make money?
Two revenue lines are on record. Brain-Computer Interface Medical Devices are the primary driver. The others are neural Data Services.
Who are Precision Neuroscience's main competitors?
Direct peers on record are Neuralink, Synchron, Blackrock Neurotech and Paradromics. Broad incumbents are Medtronic, Boston Scientific and Abbott. Emerging players are InBrain Neuroelectronics, BrainGate and Motif Neurotech.
Does Precision Neuroscience have an API?
No public API is recorded for Precision Neuroscience.
What industry is Precision Neuroscience in?
Precision Neuroscience's product category is Brain-Computer Interface Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAHAEAD, Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts). Its NAICS code is 334510 and its SIC code is 3845.